Incorrect FDA approval. The article, “Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment” (March 15, 2019, p. 362), contained an error in the last sentence of the “Anticoagulant Therapy” section in the first column of page 367, which stated that the combination of rivaroxaban (Xarelto) with aspirin had not been approved by the U.S. Food and Drug Administration (FDA) for use in patients with coronary artery disease or symptomatic peripheral artery disease. Although this statement was accurate when the article was submitted, in October 2018 the FDA issued an approval for the use of rivaroxaban in combination with aspirin “to reduce the risk of major cardiovascular events (cardiovascular [CV] death, myocardial infarction [MI] and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease.” Before publication, the article was not updated to reflect this approval. The sentence regarding lack of FDA approval has been removed.